This map shows the geographic impact of Crawford Ed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Crawford Ed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Crawford Ed more than expected).
This network shows the impact of papers produced by Crawford Ed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Crawford Ed. The network helps show where Crawford Ed may publish in the future.
Co-authorship network of co-authors of Crawford Ed
This figure shows the co-authorship network connecting the top 25 collaborators of Crawford Ed.
A scholar is included among the top collaborators of Crawford Ed based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Crawford Ed. Crawford Ed is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Ed, Crawford, et al.. (2015). Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. PubMed. 22(6). 8048–55.10 indexed citations
Ed, Crawford. (2003). The role of the urologist in treating patients with hormone-refractory prostate cancer.. Europe PMC (PubMed Central). 5 Suppl 2. S48–52.15 indexed citations
4.
Ed, Crawford, et al.. (2003). Prostate cancer update.. PubMed. 55(4). 199–204.1 indexed citations
Ziada, Ali, et al.. (2000). Advanced prostate cancer: an update.. PubMed. 2 Suppl 4. S35–9.1 indexed citations
7.
Ed, Crawford, et al.. (2000). Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy.. PubMed. 6(2). 60–3.22 indexed citations
Ed, Crawford, et al.. (1994). Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.. PubMed. Doc No 117. [4845 words; 36 paragraphs]–[4845 words; 36 paragraphs].1 indexed citations
13.
Ed, Crawford, et al.. (1990). Southwest Oncology Group Study 8710: trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080).. PubMed. 353. 111–3.15 indexed citations
14.
Blumenstein, Brent A., Crawford Ed, J. Montie, et al.. (1989). Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.. PubMed. 310. 263–70.31 indexed citations
15.
Slavík, M, et al.. (1987). Therapy for advanced renal cell cancer with spirogermanium: a Southwest Oncology Group Study.. PubMed. 71(2). 207–8.6 indexed citations
16.
Blumenstein, Brent A., et al.. (1987). Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.. PubMed. 71(12). 1305–6.1 indexed citations
17.
Ed, Crawford, et al.. (1987). Aminoglutethimide in metastatic adenocarcinoma of the prostate.. PubMed. 243A. 283–9.8 indexed citations
18.
Ed, Crawford, et al.. (1987). Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.. PubMed. 47(17). 4736–9.13 indexed citations
19.
Ed, Crawford. (1984). The Southwest Oncology Group Study for advanced testicular cancer.. PubMed. 2(4). 244–53.2 indexed citations
20.
Drelichman, Anibal, et al.. (1983). Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.. PubMed. 67(12). 1133–5.24 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.